The Stockholm Stock Exchange rose at lunchtime on Wednesday, building on gains from the previous two trading days. The leading European stock exchanges also posted gains. Verisure and Elekta presented the day's heaviest interim reports, with Elekta in particular receiving a warm reception, while Surgical Science fell heavily after a letter of intent was terminated.

At 12:55 p.m., the OMXS30 index was up 0.66 percent to 2,776.41. Shares worth approximately SEK 5.5 billion were traded on the Stockholm Stock Exchange.

Finance was the best performer among the stock market's major industrial sectors, with an increase of 1.0 percent. At the other end of the scale, telecoms was at the bottom with a gain of 0.1 percent.

Among the leading stocks included in the OMXS30 index, Boliden rose 2.9 percent, while Swedbank A was up 2.1 percent. Skanska B performed the worst, down 1.1 percent, while Atlas Copco A was down 0.3 percent.

Alarm company Verisure reported higher sales and increased adjusted operating profit in the third quarter compared with the same quarter last year. This is the first report since the company was listed on the Stockholm Stock Exchange on October 8. Annual recurring revenue rose by 10.2 percent and the number of new installations increased by 5.2 percent. The company expects annual recurring revenue to increase by more than 12 percent for the full year and adjusted operating profit to be EUR 940-950 million. The share rose 1.4 percent.

Medical technology company Elekta's operating profit in the second quarter exceeded analysts' expectations. Sales and order intake were in line with consensus. The company stands by its previous forecast for the full year 2025/26. Elekta is also implementing a cost-cutting program that will reduce costs by at least SEK 500 million annually, which means that 450 employees will be laid off. The share climbed 19 percent.

Engineering company Atlas Copco is holding a capital markets day. The company confirms its latest market outlook from its interim report on October 23. The company expects customer activity to remain at current levels.

Pharmaceutical company Astra Zeneca's combination therapy with Imfinzi has been approved in the US for stomach cancer. The share price fell 0.2 percent.

Surgical simulator company Surgical Science warned of a negative impact on its license revenues of SEK 60-90 million next year, compared with 2025. The background to this is that customer Intuitive has chosen to terminate its letter of intent with Surgical Science, which meant that the company's simulation software would be integrated into all da Vinci robot systems. The announcement caused the share price to plummet by 59 percent.

Gaming company Embracer has entered into a binding agreement to sell Arc Games and Cryptic Studios to Project Golden. The expected net proceeds from the transaction are $30 million, equivalent to SEK 287 million. The share price rose 4.8 percent.

The board of real estate company Castellum has decided on a new strategy. The goal is to achieve an annual return on equity of at least 10 percent over a business cycle. At the same time, the dividend policy will be replaced by a capital distribution policy whereby at least 25 percent of the management result will be transferred to shareholders either through cash dividends or share buybacks. The share price remained unchanged.

Greentech company Saltx Technology fell 17 percent after the company announced a rights issue of SEK 100 million.

The rise in mining company Boliden's share price is explained by Deutsche Bank raising its recommendation to buy from hold.

Vehicle safety company Autoliv rose 1.3 percent. JP Morgan raised its recommendation to overweight from neutral.

Drug development company Egetis Therapeutics fell 18 percent after Pareto Securities issued a sell recommendation.